Biogen Inc. has announced that it will present new findings at the upcoming 2025 Alzheimer's Association International Conference in Toronto, Canada, from July 27-31. The presentations will include 48-month results from the Clarity AD open-label extension study on LEQEMBI® (lecanemab), offering insights into real-world treatment and a subcutaneous formulation for maintenance dosing. Additionally, Biogen will present baseline characteristics from CELIA, a Phase 2 trial evaluating BIIB080, an investigational antisense oligonucleotide therapy targeting tau. These findings aim to advance the understanding and treatment of Alzheimer's disease. The results are set to be presented during the conference.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.